News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dynavax Technologies Corporation (DVAX) to Present at the 31st Annual J.P. Morgan Healthcare Conference


12/17/2012 10:14:04 AM

BERKELEY, CA--(Marketwire - December 17, 2012) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 7, 2013 at 6:00 p.m. Eastern Time (3:00 p.m. Pacific Time).

Dino Dina, M.D., Chief Executive Officer of Dynavax, will provide a company overview. To access the slide presentation, live webcast, and subsequent archived recording, please visit Dynavax's website at http://investors.dynavax.com/newsevents.cfm.

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Dynavax's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.


Contact:
Michael Ostrach
Vice President and Chief Business Officer
510-665-7257
Email Contact


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES